Tirzepatide vs Semaglutide

A dual GIP and GLP-1 receptor agonist producing the largest sustained weight reductions of any drug currently licensed, averaging 20–22% body weight loss in clinical trials.

A GLP-1 receptor agonist originally approved for type 2 diabetes and now widely used for chronic weight management, producing 15%+ reductions in body weight over 12 months in clinical trials.

Tirzepatide activates both GIP and GLP-1 receptors, a combination that appears to amplify glucose-dependent insulin secretion, slow gastric emptying, and suppress appetite beyond what either pathway achieves alone.

Semaglutide mimics the incretin hormone GLP-1, slowing gastric emptying, reducing appetite via hypothalamic signalling, and enhancing glucose-dependent insulin secretion. The result is sustained calorie reduction without conscious restriction.

2.5 mg weekly, titrated up to 15 mg weekly

0.25 mg weekly, titrated up to 2.4 mg weekly for weight loss

~5 days

~7 days

Subcutaneous once weekly

Subcutaneous once weekly, Oral (lower bioavailability)

approved

approved

Not yet listed

Not yet listed